US EditionFilament Health Receives First-Ever Approval for Compassionate Use of Psilocybin in the EU
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Since July of this year, in particular individual cases, it has been possible to treat patients with the psychedelic active ingredient psilocybin. Although psilocybin has not been officially approved in Germany, the substance can be used as part of a severe case program at selected sites such as Berlin and Mannheim. In Germany, for the first time, selected patients with treatment-resistant depression may receive psilocybin therapy – under strict…
Filament Health Receives First-Ever Approval for Compassionate Use of Psilocybin in the EU
The Marijuana Herald - Marijuana news and information In a historic move for psychedelic medicine, Germany has granted the first-ever compassionate use approval for psilocybin in the European Union. The authorization allows a patient with treatment-resistant depression to receive Filament Health’s botanical psilocybin drug candidate, PEX010, outside of a clinical trial setting. The treatment will be administered by Dr. Gerhard Gründer at the Ce…
Germany becomes the first EU country to allow patients legal access to a psychedelic, specifically psilocybin
Germany Establishes EU’s First Psilocybin Compassionate Access Program - Psychedelic Alpha
Germany has become the first country in the European Union to allow legal access to a psychedelic, under certain conditions, prior to regulatory approval.Through a newly established compassionate use program—which has received the blessing of the country’s drug regulator, the Federal Institute for Drugs and Medical Devices (BfArM)—two facilities are now able to offer psilocybin to adults with… Source
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
